With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...
The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...
The Shanghai-based firm will test the gene therapy candidate in patients between 4 and 9 years old with Duchenne muscular dystrophy.
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
NEW YORK – Scientists are working to better understand the role of germline pathogenic variants in the development of ductal carcinoma in situ (DCIS) and whether germline variants influence which ...
BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.
Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback